UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
July 28, 2020
Date of Report (Date of earliest event reported)
CASTLIGHT HEALTH, INC.
(Exact name of registrant as specified in its charter)

Delaware
	001-36330	26-1989091
	
(State or other jurisdiction of
incorporation)	(Commission File Number)	(I.R.S. Employer
Identification Number)	
150 Spear Street, Suite 400
San Francisco, CA 94105
(Address of principal executive offices)
(415) 829-1400
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
Not applicable

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
Class B Common Stock, par value $0.0001 per share	CSLT	New York Stock Exchange	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 28, 2020, the Company issued a press release announcing its financial results for the three months ended June 30, 2020. The press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits

Exhibit  Description

99.1 Press Release, dated July 28, 2020, entitled “Castlight Health Announces Second Quarter 2020 Results”.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CASTLIGHT HEALTH, INC.	
Date:	July 28, 2020	By:		/s/ Will Bondurant	
				Will Bondurant	
				Chief Financial Officer	

Castlight Health Announces Second Quarter 2020 Results

SAN FRANCISCO - July 28, 2020 - Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its second quarter ended June 30, 2020.

“We made meaningful headway against our strategic plan in the second quarter, delivering strong financial results, demonstrating progress toward our goal of adding an additional health plan partner, and supporting our customers with rapid innovation during COVID-19. Over the past year, we made two major strategic decisions: our focus on health plan as a key go-to-market strategy, and investment in high-tech, high-touch solutions. Our momentum in the first half of 2020 validates these decisions, and I’m confident that Castlight is strategically well positioned in the marketplace”, said Maeve O’Meara, chief executive officer of Castlight Health.

Financial performance for the three months ended June 30, 2020 compared to the three months ended June 30, 2019 includes:
•GAAP total revenue of $35.5 million, compared to $35.9 million
•GAAP gross margin of 64.1%, compared to 60.6%
•Non-GAAP gross margin of 68.3%, compared to 63.4%
•GAAP operating loss of $4.3 million, compared to $8.6 million
•Non-GAAP operating income of $2.1 million, compared to an operating loss of $2.9 million
•GAAP net loss per basic and diluted share of $0.03, compared to a net loss per basic and diluted share of $0.06

•Non-GAAP net income per basic and diluted share of $0.01, compared to a net loss per basic and diluted share of $0.02
•Cash provided by operations of $3.1 million, compared to cash used in operations of $1.8 million

Total cash, cash equivalents and marketable securities was $44.3 million as of June 30, 2020.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Business Outlook
For the full year 2020, the Company continues to expect:
•GAAP revenue in the range of $127 million to $135 million
•Non-GAAP operating loss between $17 million to $24 million
•Non-GAAP net loss per share between $0.11 and $0.16, based on approximately 150 million to 151 million shares

Quarterly Conference Call
Castlight Health senior management will host a conference call to discuss its second quarter 2020 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company’s Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. Registration for the conference call can be completed by visiting the following website prior to, or on the day of, the conference call: http://www.directeventreg.com/registration/event/3238128.

About Castlight Health
Castlight is on a mission to make it as easy as humanly possible for its users to navigate the healthcare system and live happier, healthier, more productive lives. Our health navigation platform connects hundreds of health vendors, benefits resources, and plan designs into one comprehensive health and wellbeing experience. We guide individuals—based on their unique profile—to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care. Castlight transforms the employee benefit experience into a deeply personalized, yet simple, guided one, empowering better-informed patient decisions to unlock better healthcare outcomes and maximizing return on healthcare investments.

For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures
To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude goodwill impairment, stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, capitalization and amortization of internal-use software, and lease exit and related charges.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2020 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s second quarter performance and 2020 full year projections, impact of COVID-19, the success of our strategy and our expectations for our future business and financial performance. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission, including the risks set forth in our annual report on Form 10-K filed on February 28, 2020, and our quarterly report on Form 10-Q for the three months ended June 30, 2020, when filed. All forward-looking statements in this press release are expressly qualified in their entirety by these cautionary statements and are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2020 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)

	As of	
	June 30, 2020		December 31, 2019	
Assets				
Current assets:				
Cash and cash equivalents	$	44,274 	 		$	43,017 	 	
Marketable securities	— 	 		16,411 	 	
Accounts receivable and other, net	33,175 	 		31,397 	 	
Prepaid expenses and other current assets	5,643 	 		4,645 	 	
Total current assets	83,092 	 		95,470 	 	
Property and equipment, net	6,353 	 		4,856 	 	
Restricted cash, non-current	1,144 	 		1,144 	 	
Deferred commissions	11,719 	 		14,718 	 	
Deferred professional service costs	5,717 	 		6,711 	 	
Intangible assets, net	10,046 	 		12,178 	 	
Goodwill	41,485 	 		91,785 	 	
Operating lease right-of-use assets, net	11,122 	 		13,906 	 	
Other assets	1,595 	 		2,016 	 	
Total assets	$	172,273 	 		$	242,784 	 	
Liabilities and stockholders’ equity				
Current liabilities:				
Accounts payable	$	8,606 	 		$	19,596 	 	
Accrued expenses and other current liabilities	8,887 	 		10,454 	 	
Accrued compensation	5,656 	 		8,770 	 	
Deferred revenue	12,930 	 		10,173 	 	
Operating lease liabilities	5,429 	 		5,914 	 	
Total current liabilities	41,508 	 		54,907 	 	
Deferred revenue, non-current	577 	 		572 	 	
Debt, non-current	465 	 		1,395 	 	
Operating lease liabilities, non-current	9,290 	 		11,823 	 	
Other liabilities, non-current	1,269 	 		1,213 	 	
Total liabilities	53,109 	 		69,910 	 	
Stockholders’ equity	119,164 	 		172,874 	 	
Total liabilities and stockholders’ equity	$	172,273 	 		$	242,784 	 	

CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)

 	Three Months Ended June 30,		Six Months Ended June 30,	
	2020		2019		2020		2019	
Revenue:								
Subscription	$	34,289 	 		$	33,964 	 		$	72,672 	 		$	67,770 	 	
Professional services and other	1,211 	 		1,946 	 		1,873 	 		3,630 	 	
Total revenue, net	35,500 	 		35,910 	 		74,545 	 		71,400 	 	
Cost of revenue:								
Cost of subscription(1)	8,819 	 		8,234 	 		19,051 	 		16,400 	 	
Cost of professional services and other(1)	3,942 	 		5,929 	 		8,183 	 		11,873 	 	
Total cost of revenue	12,761 	 		14,163 	 		27,234 	 		28,273 	 	
Gross profit	22,739 	 		21,747 	 		47,311 	 		43,127 	 	
Operating expenses:								
Sales and marketing(1)	7,683 	 		8,889 	 		18,155 	 		18,104 	 	
Research and development(1)	13,043 	 		14,487 	 		26,865 	 		30,212 	 	
General and administrative(1)	6,340 	 		7,010 	 		12,916 	 		14,303 	 	
Goodwill impairment	— 	 		— 	 		50,300 	 		— 	 	
Total operating expenses	27,066 	 		30,386 	 		108,236 	 		62,619 	 	
Operating loss	(4,327)	 		(8,639)	 		(60,925)	 		(19,492)	 	
Other income, net	123 	 		258 	 		386 	 		572 	 	

Net loss	$	(4,204)	 		$	(8,381)	 		$	(60,539)	 		$	(18,920)	 	
Net loss per share, basic and diluted	$	(0.03)	 		$	(0.06)	 		$	(0.41)	 		$	(0.13)	 	
Weighted-average shares used to compute basic and diluted net loss per share	150,078 	 		144,572 	 		149,475 	 		143,790 	 	

(1)Includes stock-based compensation expense as follows:
																								
 	Three Months Ended June 30,		Six Months Ended June 30,	
 	2020		2019		2020		2019	
Cost of revenue:								
Cost of subscription	$	205 	 		$	196 	 		$	374 	 		$	415 	 	
Cost of professional services and other	144 	 		236 	 		260 	 		501 	 	
Sales and marketing	748 	 		662 	 		1,420 	 		1,289 	 	
Research and development	1,314 	 		1,733 	 		2,477 	 		3,437 	 	
General and administrative	858 	 		2,030 	 		1,924 	 		3,192 	 	

CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
																								
 	Three Months Ended June 30,		Six Months Ended June 30,	
 	2020		2019		2020		2019	
Operating activities:								
Net loss	$	(4,204)	 		$	(8,381)	 		$	(60,539)	 		$	(18,920)	 	
Adjustments to reconcile net loss to net cash used in operating activities:								
Depreciation and amortization	1,609 	 		1,343 	 		3,144 	 		2,687 	 	
Goodwill impairment	— 	 		— 	 		50,300 	 		— 	 	
Stock-based compensation	3,269 	 		4,857 	 		6,455 	 		8,834 	 	
Amortization of deferred commissions	1,536 	 		2,365 	 		3,919 	 		4,856 	 	
Amortization of deferred professional service costs	732 	 		1,045 	 		1,657 	 		2,014 	 	
Non-cash operating lease expense	1,231 	 		1,298 	 		2,631 	 		2,580 	 	

	
Accretion and amortization of marketable securities	— 	 		(87)	 		2 	 		(213)	 	
Changes in operating assets and liabilities:								
Accounts receivable and other, net	4,898 	 		2,088 	 		(1,778)	 		(5,795)	 	
Deferred commissions	(602)	 		(1,254)	 		(920)	 		(2,670)	 	
Deferred professional service costs	(213)	 		(432)	 		(629)	 		(901)	 	
Prepaid expenses and other assets	(330)	 		(1,113)	 		(824)	 		(1,864)	 	
Accounts payable	(2,739)	 		2,713 	 		(10,201)	 		1,864 	 	
Operating lease liabilities	(1,100)	 		(1,413)	 		(2,616)	 		(2,795)	 	
Accrued expenses and other liabilities	(1,530)	 		(1,827)	 		(1,511)	 		(3,131)	 	
Deferred revenue	(811)	 		(3,183)	 		2,762 	 		312 	 	
Accrued compensation	1,351 	 		164 	 		(3,114)	 		(806)	 	
Net cash provided by (used in) operating activities	3,097 	 		(1,817)	 		(11,262)	 		(13,948)	 	
Investing activities:								
Purchase of property and equipment	(2,035)	 		(389)	 		(3,299)	 		(593)	 	
Purchase of marketable securities	(1,005)	 		(13,780)	 		(2,994)	 		(13,780)	 	
Sales of marketable securities	2,001 	 		— 	 		2,001 	 		— 	 	
Maturities of marketable securities	5,000 	 		— 	 		17,400 	 		11,453 	 	
	
Net cash provided by (used in) investing activities	3,961 	 		(14,169)	 		13,108 	 		(2,920)	 	
Financing activities:								
	
Proceeds from exercise of stock options	— 	 		165 	 		155 	 		1,845 	 	
Proceeds from ESPP offering	— 	 		— 	 		186 	 		— 	 	
Principal payments on long-term debt	(465)	 		(465)	 		(930)	 		(930)	 	
Net cash (used in) provided by financing activities	(465)	 		(300)	 		(589)	 		915 	 	
								
Net increase (decrease) in cash, cash equivalents and restricted cash	6,593 	 		(16,286)	 		1,257 	 		(15,953)	 	
Cash, cash equivalents and restricted cash at beginning of period	39,006 	 		67,663 	 		44,342 	 		67,330 	 	
Cash, cash equivalents and restricted cash at end of period	$	45,599 	 		$	51,377 	 		$	45,599 	 		$	51,377 	 	
								
Reconciliation of cash, cash equivalents and restricted cash:								
Cash and cash equivalents	$	44,274 	 		$	50,052 	 		$	44,274 	 		$	50,052 	 	
Restricted cash included in Prepaid expenses and other current assets	181 	 		— 	 		181 	 		— 	 	
Restricted cash, non-current	1,144 	 		1,325 	 		1,144 	 		1,325 	 	
Total cash, cash equivalents and restricted cash	$	45,599 	 		$	51,377 	 		$	45,599 	 		$	51,377 	 	

CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

																														
	Three Months Ended		Six Months Ended	
	June 30, 2020		March 31, 2020		June 30, 2019		June 30, 2020		June 30, 2019	
Gross profit:										
GAAP gross profit subscription	$	25,470 	 		$	28,151 	 		$	25,730 	 		$	53,621 	 		$	51,370 	 	
Stock-based compensation	205 	 		169 	 		196 	 		374 	 		415 	 	
Amortization of internal-use software	79 	 		26 	 		— 	 		105 	 		— 	 	
Amortization of intangibles	530 	 		530 	 		587 	 		1,060 	 		1,174 	 	
Reduction in workforce	221 	 		— 	 		— 	 		221 	 		— 	 	
	
Non-GAAP gross profit subscription	$	26,505 	 		$	28,876 	 		$	26,513 	 		$	55,381 	 		$	52,959 	 	
GAAP gross margin subscription	74.3 	%		73.3 	%		75.8 	%		73.8 	%		75.8 	%	
Non-GAAP gross margin subscription	77.3 	%		75.2 	%		78.1 	%		76.2 	%		78.1 	%	
										
GAAP gross loss professional services	$	(2,731)	 		$	(3,579)	 		$	(3,983)	 		$	(6,310)	 		$	(8,243)	 	
Stock-based compensation	144 	 		116 	 		236 	 		260 	 		501 	 	
Reduction in workforce	317 	 		— 	 		— 	 		317 	 		— 	 	
	
Non-GAAP gross loss professional services	$	(2,270)	 		$	(3,463)	 		$	(3,747)	 		$	(5,733)	 		$	(7,742)	 	
GAAP gross margin professional services	(226)	%		(541)	%		(205)	%		(337)	%		(227)	%	
Non-GAAP gross margin professional services	(187)	%		(523)	%		(193)	%		(306)	%		(213)	%	
										
GAAP gross profit	$	22,739 	 		$	24,572 	 		$	21,747 	 		$	47,311 	 		$	43,127 	 	
Impact of non-GAAP adjustments	1,496 	 		841 	 		1,019 	 		2,337 	 		2,090 	 	
Non-GAAP gross profit	$	24,235 	 		$	25,413 	 		$	22,766 	 		$	49,648 	 		$	45,217 	 	
GAAP gross margin	64.1 	%		62.9 	%		60.6 	%		63.5 	%		60.4 	%	
Non-GAAP gross margin	68.3 	%		65.1 	%		63.4 	%		66.6 	%		63.3 	%	
										
Operating expense:										
GAAP sales and marketing	$	7,683 	 		$	10,472 	 		$	8,889 	 		$	18,155 	 		$	18,104 	 	
Stock-based compensation	(748)	 		(672)	 		(662)	 		(1,420)	 		(1,289)	 	
Amortization of intangibles	(528)	 		(528)	 		(272)	 		(1,056)	 		(544)	 	
Reduction in workforce	(334)	 		— 	 		— 	 		(334)	 		— 	 	
Non-GAAP sales and marketing	$	6,073 	 		$	9,272 	 		$	7,955 	 		$	15,345 	 		$	16,271 	 	
										
GAAP research and development	$	13,043 	 		$	13,822 	 		$	14,487 	 		$	26,865 	 		$	30,212 	 	
Stock-based compensation	(1,314)	 		(1,163)	 		(1,733)	 		(2,477)	 		(3,437)	 	
Reduction in workforce	(658)	 		— 	 		— 	 		(658)	 		— 	 	
	
Certain legal expenses	— 	 		191 	 		— 	 		191 	 		(191)	 	
Capitalization of internally developed software	— 	 		21 	 		— 	 		21 	 		— 	 	
	
Non-GAAP research and development	$	11,071 	 		$	12,871 	 		$	12,754 	 		$	23,942 	 		$	26,584 	 	
										
GAAP general and administrative	$	6,340 	 		$	6,576 	 		$	7,010 	 		$	12,916 	 		$	14,303 	 	
Stock-based compensation	(858)	 		(1,066)	 		(2,030)	 		(1,924)	 		(3,192)	 	
	
Amortization of intangibles	— 	 		(17)	 		(17)	 		(17)	 		(34)	 	
	
Certain legal expenses	— 	 		— 	 		— 	 		— 	 		(533)	 	
Reduction in workforce	(497)	 		— 	 		— 	 		(497)	 		— 	 	
Non-GAAP general and administrative	$	4,985 	 		$	5,493 	 		$	4,963 	 		$	10,478 	 		$	10,544 	 	
										
GAAP goodwill impairment	$	— 	 		$	50,300 	 		$	— 	 		$	50,300 	 		$	— 	 	
Goodwill impairment	— 	 		(50,300)	 		— 	 		(50,300)	 		— 	 	
Non-GAAP goodwill impairment	$	— 	 		$	— 	 		$	— 	 		$	— 	 		$	— 	 	

CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)

GAAP operating expense	$	27,066 	 		$	81,170 	 		$	30,386 	 		$	108,236 	 		$	62,619 	 	
Impact of non-GAAP adjustments	(4,937)	 		(53,534)	 		(4,714)	 		(58,471)	 		(9,220)	 	
Non-GAAP operating expense	$	22,129 	 		$	27,636 	 		$	25,672 	 		$	49,765 	 		$	53,399 	 	
										
Operating loss:										
GAAP operating loss	$	(4,327)	 		$	(56,598)	 		$	(8,639)	 		$	(60,925)	 		$	(19,492)	 	
Impact of non-GAAP adjustments	6,433 	 		54,375 	 		5,733 	 		60,808 	 		11,310 	 	
Non-GAAP operating income (loss)	$	2,106 	 		$	(2,223)	 		$	(2,906)	 		$	(117)	 		$	(8,182)	 	

	

	
										
Net loss and net loss per share:										
GAAP net loss	$	(4,204)	 		$	(56,335)	 		$	(8,381)	 		$	(60,539)	 		$	(18,920)	 	
Total pre-tax impact of non-GAAP adjustments	6,433 	 		54,375 	 		5,733 	 		60,808 	 		11,310 	 	
	
Non-GAAP net income (loss)	$	2,229 	 		$	(1,960)	 		$	(2,648)	 		$	269 	 		$	(7,610)	 	
GAAP net loss per share, basic and diluted	$	(0.03)	 		$	(0.38)	 		$	(0.06)	 		$	(0.41)	 		$	(0.13)	 	
Non-GAAP net income (loss) per share, basic and diluted	$	0.01 	 		$	(0.01)	 		$	(0.02)	 		$	— 	 		$	(0.05)	 	
Shares used in basic and diluted net loss per share computation	150,078 	 		148,872 	 		144,572 	 		149,475 	 		143,790 	 	

Castlight Media Contact:
Caroline Kawashima
press@castlighthealth.com
415-246-0313

Castlight Investor Contact:
ir@castlighthealth.com
415-829-1680